Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.56 |
| ▸ | ACACA | Q13085 | 2/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541985 | 0.85 | NOTUM (0.51) | SCN5ASCN10ASMN1; SMN2TDP1NPC1 | |
| SCHEMBL6528165 | 0.85 | NOTUM (0.69) | SCN5ASCN10ASMN1; SMN2TDP1NPC1 | |
| SCHEMBL201607 | 0.83 | NOTUM (0.70) | ACACBACACASCN5ASCN10ASMN1; SMN2 | |
| SCHEMBL5311162 | 0.83 | ACACB (0.59) | ACACBACACASCN5ASCN10ASMN1; SMN2 | |
| SCHEMBL14441200 | 0.83 | MAPK1 (0.54) | SCN5ASCN10ASMN1; SMN2TDP1NPC1 | |
| SCHEMBL12168972 | 0.81 | RAB9A (0.47) | ACACBACACASMN1; SMN2TDP1NPC1 | |
| SCHEMBL10053485 | 0.81 | SMN1; SMN2 (0.63) | ACACBACACASMN1; SMN2TDP1NPC1 | |
| SCHEMBL12525780 | 0.81 | MAPT (0.61) | ACACBACACASMN1; SMN2TDP1NPC1 | |
| SCHEMBL8592557 | 0.79 | ACACB (0.59) | ACACBACACASMN1; SMN2TDP1NPC1 | |
| SCHEMBL6112858 | 0.79 | ACACB (0.59) | ACACBACACASMN1; SMN2TDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-01-18 | — | — | US | disclosed |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-8486981-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2012121919-A2 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120232118-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | UNIVERSITY OF KANSAS (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232118-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | DRD3, SLC6A3, OPRD1 | ACACB 4825/4885ACACA 4639/4885SCN5A 3496/4885 |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | DDT, CYP3A43, CYP19A1 | ACACB 707/4885ACACA 360/4885SCN5A 778/4885 |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | GTF3C4, BRD4, CUL4B | ACACB 1773/4885ACACA 2760/4885SCN5A 248/4885 |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | ACACB 4773/4885ACACA 4445/4885SCN5A 10/4885 |
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ACACB 2232/4885ACACA 2102/4885SCN5A 3383/4885 |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | DDT, CYP3A43, CYP19A1 | ACACB 707/4885ACACA 360/4885SCN5A 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.